Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit
Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit
REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced today announced that its management will present at the Oppenheimer Novel Targets in Immunology Summit, to be held on Monday, June 24, 2024, in New York City.
加帕瑟治療公司(Jasper Therapeutics, Inc.)(納斯達克代碼:JSPR)是一家專注於開發新型抗體治療對甲狀腺細胞驅動的疾病有顯著作用的briquilimab的生物技術公司,所涵蓋的領域是慢性自發性蕁麻疹 (CSU)、慢性誘發性蕁麻疹(CIndU)以及哮喘。今天宣佈管理層將於2024年6月24日星期一在紐約市舉行的Oppenheimer Novel Targets in Immunology Summit上發表演講。
Oppenheimer Novel Targets in Immunology Summit
Presentation Date/Time: Monday, June 24, 2024; 11:45 a.m. EDT
Presentation Format: Panel Discussion – "Novel Immunological Mechanisms for Dermatologic Disorders"
Oppenheimer Novel Targets in Immunology Summit
發言日期/時間:2024年6月24日星期一;東部時間上午11:45。
發言形式:分組討論-“治療皮膚疾病的新型免疫機制”
About Jasper
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia, MDS, FA, and SCD. For more information, please visit us at www.jaspertherapeutics.com.
關於Jasper
Jasper是一家臨床階段的生物技術公司,開發的briquilimab是一種單克隆抗體,針對c-Kit(CD117),作爲針對慢性肥大和幹細胞疾病,如慢性蕁麻疹和較低到中等風險的骨髓增生異常綜合症(MDS),以及作爲幹細胞移植的一種調理劑,用於罕見疾病,如鐮狀細胞貧血(SCD)、範可尼貧血(FA)和嚴重的聯合免疫缺陷(SCID)。迄今爲止,briquilimab在145名接受劑量試驗的參與者和健康志願者中展示出顯著的療效和安全性,臨床結果顯示勝任SCID、急性髓細胞白血病、MDS、FA和SCD的調理劑。欲了解更多信息,請訪問我們的網站。www.jaspertherapeutics.com.
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Jasper's presentation at the Oppenheimer Novel Targets in Immunology Summit, and briquilimab's potential to address mast cell driven diseases such as CSU, CIndU and asthma. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
前瞻性聲明
本新聞稿中包含的某些並非歷史事實的聲明,屬於安全港規定下根據《1995年美國私人證券訴訟改革法》的前瞻性聲明。前瞻性聲明有時伴隨着“相信”、“可能”、“將”、“估計”、“持續”、“預計”、“應該”、“將要”、“計劃”、“預測”、“潛力”、“看起來”、“尋求”、“未來”、“展望”和類似的表達方式,以預測或指示未來事件或趨勢,或不是歷史事項的表述。這些前瞻性聲明包括但不限於,關於Jasper在Oppenheimer Novel Targets in Immunology Summit上的介紹,以及briquilimab治療肥大細胞驅動的疾病(如CSU、CIndU和哮喘)的潛力。這些聲明基於各種是否在本新聞稿中識別的假設以及基於Jasper的當前期望,不是實際績效的預測。這些前瞻性聲明僅用於說明目的,並不意味着它們將作爲投資者的保證、保障、預測或確定的事實或概率,被投資者依賴。許多實際事件和情況超出了Jasper的控制範圍。這些前瞻性聲明受到許多風險和不確定因素的影響,包括一般經濟、政治和商業條件;Jasper開發的潛在候選產品可能無法按預期時間線或根本不獲得所需的監管批准;臨床試驗可能無法證實本新聞稿中描述或假定的任何安全性、效力或其他產品特性;Jasper無法成功營銷或獲得其產品候選者的市場認可的風險;先前的研究結果可能無法複製;Jasper的產品候選者可能無法對患者產生益處或成功商業化;患者願意嘗試新的治療方式以及醫生使用這些治療方式的意願;競爭對Jasper的業務產生影響;Jasper依賴於的爲其實驗室、臨床開發、生產和其他關鍵服務的第三方可能無法滿意地履行職責;Jasper的業務、運營、臨床開發計劃和時間表以及供應鏈可能會受到健康流行病等因素的不利影響;Jasper將無法爲其調查產品獲得並保持足夠的知識產權保護,或將侵犯他人的知識產權保護;以及Jasper在SEC的備案中不時指出的其他風險和不確定因素,包括其於2023年12月31日結束的第10-K表和其隨後的第10-Q表的年度報告書。如果這些風險中的任何一種成爲現實,或者Jasper的假設被證明是不正確的,實際結果可能會與這些前瞻性聲明所暗示的結果有很大的不同。雖然Jasper可能會在未來的某個時間選擇更新這些前瞻性聲明,但Jasper明確否認有任何義務這樣做。這些前瞻性聲明不應該被作爲Jasper對本新聞稿發佈日期後任何日期的評估的表示。因此,不應過度依賴於這些前瞻性聲明。
Contacts:
Joyce Allaire (investors)
LifeSci Advisors
617-435-6602
jallaire@lifesciadvisors.com
聯繫人:
Joyce Allaire(投資人)
LifeSci Advisors
617-435-6602
jallaire@lifesciadvisors.com
Alex Gray (investors)
Jasper Therapeutics
650-549-1454
agray@jaspertherapeutics.com
Alex Gray(投資人)
Jasper治療
650-549-1454
agray@jaspertherapeutics.com
Lauren Walker (media)
Real Chemistry
646-564-2156
lbarbiero@realchemistry.com
Lauren Walker(媒體)
Real Chemistry
646-564-2156
lbarbiero@realchemistry.com